|
|
| Nomenclature |
|
Symbol:
|
Tg(Ins2-Tag*,-flpe)#Gne
|
|
Name:
|
transgene insertion, Genentech
|
|
MGI ID: |
MGI:5441546 |
|
Synonyms: |
RIP-TbetaAg |
|
Transgene:
|
Tg(Ins2-Tag*,-flpe)#Gne
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
Not Specified
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (Cre/Flp) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: This transgene consists of 2 co-injected constructs. The first construct contains the rat insulin promoter followed by an SV40 T antigen in which the two exons are interrupted by an FRT flanked beta-globin intron. The second construct contains he rat insulin promoter followed by a flpe gene. Recombination and expression of the transgene is seen in the pancreas. Absence of recombination in the liver and spleen was confirmed by PCR analysis. (J:187012)
|
|
|
Recombinase activity
|
|
Driver:
|
Ins2
Summary of all recombinase alleles
driven by Ins2.
|
|
MGI has not yet included tissue activity data for this allele in any anatomical systems.
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available |
|
| References |
|
Original: |
J:188693
Bagri A et al.,
"Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy."
Clin Cancer Res 2010 Aug 1;16(15):3887-900
|
|
All: |
2 reference(s)
|
|
Analysis Tools
